# A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

> **NCT02195349** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 67 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** GSK2831781
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02195349
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-30
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-03-07
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2021-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195349, "A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02195349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*